bosentan anhydrous has been researched along with Cryptogenic Fibrosing Alveolitis in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Guo, X; Lian, H; Rosas, I; Wang, L; Wang, N; Xia, C; Xu, K; Yang, J; Yu, G; Zhao, W | 1 |
| Sakao, S; Tanabe, N; Tatsumi, K | 1 |
| Sakao, S | 1 |
| Gemma, A; Hino, M; Tanaka, Y | 1 |
| Behr, J; Bonella, F; Costabel, U; Geißler, K; Günther, A; Koschel, D; Kreuter, M; Müller-Quernheim, J; Prasse, A; Schönfeld, N; Sitter, H | 1 |
| Babalis, D; Birring, SS; Corris, PA; Corte, TJ; Dimopoulos, K; Elliot, CA; Foley, C; Gatzoulis, MA; Howard, L; Keir, GJ; Maher, TM; Marino, P; O'Reilly, K; Parfitt, L; Renzoni, EA; Spencer, L; Wells, AU; Wort, SJ; Yanez-Lopez, M | 1 |
| Chilakapati, DR; Chilakapati, SR; Kanala, JR; Serasanambati, M; Vissavajjhala, P | 1 |
| Canestaro, WJ; Devine, BE; Forrester, SH; Ho, L; Raghu, G | 1 |
| Behr, J; Brown, KK; du Bois, RM; King, TE; Raghu, G; Swigris, JJ; Wamboldt, FS | 1 |
| Jones, PW; Swigris, JJ; Yorke, J | 1 |
| Behr, J; Brown, KK; du Bois, RM; King, TE; Leconte, I; Lynch, DA; Martinez, F; Morganti, A; Raghu, G; Roux, S; Valeyre, D | 1 |
| Kaminski, N; Noble, PW; Richeldi, L | 1 |
| Cerri, S; Luppi, F; Richeldi, L; Spagnolo, P | 1 |
3 review(s) available for bosentan anhydrous and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis.
Topics: Bosentan; Disease Progression; Endothelin Receptor Antagonists; Enzyme Activators; Humans; Hypertension, Pulmonary; Hypoxia; Idiopathic Pulmonary Fibrosis; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Circulation; Pulmonary Diffusing Capacity; Pulmonary Ventilation; Pyrazoles; Pyrimidines; Sildenafil Citrate; Treatment Failure; Vascular Remodeling; Vasoconstriction | 2019 |
Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
Topics: Acetylcysteine; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Azathioprine; Bayes Theorem; Bosentan; Endothelin Receptor Antagonists; Enzyme Inhibitors; Etanercept; Free Radical Scavengers; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Interferon-gamma; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Recombinant Proteins; Sulfonamides; Vital Capacity; Warfarin | 2016 |
The big clinical trials in idiopathic pulmonary fibrosis.
Topics: Bosentan; Humans; Idiopathic Pulmonary Fibrosis; Pyridones; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2012 |
5 trial(s) available for bosentan anhydrous and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis-an interim analysis of results from a prospective, single-center, randomized, parallel-group study.
Topics: Activities of Daily Living; Aged; Bosentan; Echocardiography; Endothelin Receptor Antagonists; Female; Heart; Hospitalization; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Lung; Male; Middle Aged; Prospective Studies; Respiratory Function Tests; Sulfonamides; Survival Analysis; Treatment Outcome | 2017 |
Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension, Pulmonary; Idiopathic Interstitial Pneumonias; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Sulfonamides; Treatment Outcome; Vascular Resistance; Young Adult | 2014 |
The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.
Topics: Aged; Antihypertensive Agents; Bosentan; Double-Blind Method; Exercise Test; Female; Follow-Up Studies; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Prospective Studies; Sulfonamides; Treatment Outcome; Vital Capacity; Walking | 2010 |
Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire.
Topics: Aged; Antihypertensive Agents; Bosentan; Epidemiologic Methods; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Quality of Life; Severity of Illness Index; Sulfonamides; Surveys and Questionnaires; Treatment Outcome; Vital Capacity | 2010 |
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Disease Progression; Double-Blind Method; Endpoint Determination; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pulmonary Diffusing Capacity; Quality of Life; Sulfonamides; Survival Rate; Vital Capacity | 2011 |
5 other study(ies) available for bosentan anhydrous and Cryptogenic Fibrosing Alveolitis
| Article | Year |
|---|---|
Endothelial cell-derived MMP19 promotes pulmonary fibrosis by inducing E(nd)MT and monocyte infiltration.
Topics: Animals; Bleomycin; Bosentan; Endothelial Cells; Epithelial-Mesenchymal Transition; Humans; Idiopathic Pulmonary Fibrosis; Lung; Matrix Metalloproteinases, Secreted; Mice; Monocytes | 2023 |
Chronic lung disease-associated PH: PAH-approved drugs and established universal healthcare insurance in Japan.
Topics: Bosentan; Humans; Hypertension, Pulmonary; Idiopathic Pulmonary Fibrosis; Insurance Coverage; Japan; Phenylpropionates; Prevalence; Prognosis; Pulmonary Disease, Chronic Obstructive; Pyrazoles; Pyridazines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Universal Health Insurance | 2020 |
German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017.
Topics: Acetylcysteine; Adult; Aged; Aged, 80 and over; Antacids; Bosentan; Clinical Trials as Topic; Evidence-Based Medicine; Female; Gastroesophageal Reflux; Guideline Adherence; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Indoles; Male; Middle Aged; Phenylpropionates; Pyridazines; Pyridones; Pyrimidines; Sildenafil Citrate; Sulfonamides | 2018 |
Amelioration of bleomycin-induced pulmonary fibrosis in a mouse model by a combination therapy of bosentan and imatinib.
Topics: Actins; Animals; Anti-Inflammatory Agents; Bleomycin; Bosentan; Catalase; Collagen Type I; Collagen Type II; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Hydroxyproline; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Lung; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice, Inbred C57BL; Oxidative Stress; Peroxidase; Pneumonia; Pulmonary Edema; RNA, Messenger; Sulfonamides; Superoxide Dismutase; Time Factors | 2015 |
End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endpoint Determination; Humans; Idiopathic Pulmonary Fibrosis; Sulfonamides; Treatment Outcome | 2011 |